Login to Your Account

AtheroGenics Drops AGIX-4207 After Phase II Miss In Arthritis

By Aaron Lorenzo

Thursday, October 14, 2004
AtheroGenics Inc. is discontinuing the development of one of its investigational drugs following a Phase II failure. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription